Biotechnology Companies in the News – December 2011

December 2
Bristol-Myers Squibb Enters Clinical Collaboration Agreement with Tibotec Pharmaceuticals for Phase II Combination Study in Patients Chronically Infected with Hepatitis C

December 1
NPS Pharmaceuticals Completes Submission of New Drug Application for GATTEX(R) (teduglutide) in Adult Short Bowel Syndrome (SBS)

Aegerion Pharmaceuticals to Participate in the 2011 Deutsche Bank BioFEST Conference

Amicus Therapeutics Announces First Patient in Phase 2 Study for Pompe Disease

Celldex Initiates ACT IV, a Pivotal International Phase 3 Trial of Rindopepimut in Patients with Glioblastoma

Cyclacel to Webcast Analyst & Institutional Investor Meeting Wednesday, December 7, 2011

Senesco Receives Milestone Payment from Bayer CropScience

November 30
Unigene’s Proprietary Peptelligence™ Platform Used to Commence Cara Therapeutics Phase 1 Clinical Trial of Oral Novel Peripherally-Acting Kappa Opioid Agonist

CircuLite® Raises $30 Million Series D Financing

Alvin Ailey American Dance Theater Premieres Home, a New Work Inspired by the Winning Photos and Essays from the 2011 REYATAZ®(atazanavir sulfate) “Fight HIV Your Way” Contest, an Initiative of Bristol-Myers Squibb

The Medicines Company to Participate in the 2011 Deutsche Bank BioFEST

November 29
Alliance Life Sciences Issues White Paper: “Federal and State Sunshine Act Compliance Readiness” Addresses Lack of Direction from CMS

NPS Pharmaceuticals to Present at Deutsche Bank BioFEST Conference

FDA Accepts ELIQUIS® (apixaban) New Drug Application for Review for the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation

Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)

November 25
Celgene Corporation to Present at the Piper Jaffray Health Care Conference 2011

November 23
A Tribute to Alex Barkas

Advaxis Completes Pre-IND Meeting for ADXS-HER2

November 22
Lexicon Announces Commencement of Rights Offering to Stockholders

Senesco to Present at NYSSA’s 2011 Biotech / Specialty Pharma Conference

Bio-Reference Laboratories, Inc. and McKesson Specialty Health’s Onmark GPO Execute Purchasing Agreement

Pacira Pharmaceuticals, Inc. Announces Completion of Follow-on Offering of Common Stock and Exercise of Over-Allotment Option

November 21
Celldex Therapeutics Reports Positive Mature Survival Data from Rindopepimut Phase 2 Brain Cancer Study at SNO 2011

Gilead Sciences to Acquire Pharmasset, Inc. for $11 Billion

Savara Inc. Joins SAFE-BioPharma Association

Hoping Pharmasset Gains Jobs After Being Sold to Calif. Biotech in $11B deal

November 18
Bio-Reference Laboratories’ CEO Marc Grodman MD Speaks at Capitol Hill Policy Forum on the Contribution Genetic Tests Are Making to Cancer Care

November 17
Edge Therapeutics Appoints James J. Loughlin to Board of Directors

Bristol-Myers Squibb Foundation Awards $2.34 Million in Grants to Help Prisoners with Mental Illness Return to Community

November 16
Unigene Strengthens Board with the Appointment of Walgreen’s Executive, Thomas J. Sabatino, Jr.-Board Strengthened with Extensive Healthcare and Legal Expertise-

Meta-Analysis of Clinical Data on Cardiovascular Safety Presented for Investigational Compound Dapagliflozin in Adult Patients with Type 2 Diabetes

November 15
Immunomedics Awarded Additional U.S. Patent for Anti-Cd20 Treatment of Autoimmune Diseases

Bio-Reference Laboratories Named 8th Fastest Growing Company in State of New Jersey

Advaxis Licenses Novel Antigen for Severe Breast Cancer and Other Tumor Types

November 14
Bristol-Myers Squibb Foundation’s Together on Diabetes® Initiative Marks First Anniversary by Awarding $18.4 Million in Grants to Help Communities Hardest Hit by Diabetes, Issuing Annual Report

Unigene Announces Novartis’ Disclosure of First Interpretable Results from Phase 3 Trial of Calcitonin (SMC021) in the Treatment of Post-menopausal Osteoporosis

DuPont Crop Protection and BioLeap Enter Research Collaboration

Soligenix Reports Third Quarter 2011 Financial Results

Cyclacel Pharmaceuticals Reports Third Quarter 2011 Financial Results

Pharmasset Reports Fiscal Year End 2011 Financial Results

The Medicines Company’s MDCO-216 (ApoA-I Milano Complex) Demonstrates Capacity to Clear Cholesterol from Cells in Preclinical Model

November 13
New Data Presented on Phase 3 Trial Of ELIQUIS®(apixaban) in the Prevention of Venous Thromboembolism in Patients with Acute Medical Illness

Pharmasset to Present at the Lazard Capital Markets Healthcare Conference

November 12
Enzon Presents Clinical and Preclinical Data on mRNA Antagonists at 2011 AACR-NCI-EORTC Meeting

November 11
Derma Sciences Reports Third Quarter Financial and Operating Results; End-of-Phase 2 Meeting Set with FDA

Bristol-Myers Squibb Signs New Agreement to Expand Access to Reyataz®(atazanavir sulfate) in Brazil

Immunomedics Receives Thomas Alva Edison Patent Award from Research & Development Council Of New Jersey

Bio-Reference Laboratories, Inc. Announces Stock Buy-Back Plan

Lexicon Announces Plans for Rights Offering to Stockholders

November 10
CorMedix Reports Third Quarter 2011 Results

November 9
Amicus Therapeutics to Present at Lazard Capital Markets 8th Annual Healthcare Conference on Wednesday, November 16, 2011